Genmab — Februar 2021
-
God morgen
-
God morgen.
-
Fredagens aviser med SAS, ISS og Danske Bank
-
Nektar Therapeutics apparently entered into a drug supply collaboration with Janssen late last year for the DARZALEX FASPRO supply for the NKTR-255 combo study. Not sure if that implies JNJ believes in the combo https://www.nasdaq.com/articles/nektar-therapeutics-nktr-q4-2020-earnings-call-transcript-2021-02-26
-
"MacKay expects Genmab A/S to post earnings per share (EPS) of $0.00 for the first quarter of 2021" - hvordan læser i denne sætning?
-
Ja, så passer det fint med, at RBC hæver deres target til 46 usd
-
Hæver
-
= fastholder....
-
I am not sure I had seen this comment from Jan: - Analytikere estimerer, at det er et marked på over 10 mia. dollar. Der vil være konkurrence fra andre lægemidler, men vi håber, at kunne positionere det til tage i størrelsesordenen 5 mia. dollar plus, siger Jan van de Winkel. -from https://borsen.dk/investor/aktie/S1073/GMAB/Genmab 23Feb
-
I certainly missed it - the comment goes perfectly with their aspiration to become backbone treatment
-
Stockbull - du skal tænke mere på det tilbagediskonterede cashflow end balancen. Diskonteringsfaktoren stiger og dermed falder nutidsværdien af det fremtidige cashflow.
-
Dermed bliver alternative investeringer - obligationer og value aktier mere interessante, og så kommer der et smæk mere
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind